Get the full TYLsemi company profile
Access contacts, investors, buying signals & more
The complex demands of AI infrastructure silicon, particularly in power, IO, and memory, have drawn significant investor interest to TYLsemi. The company, which addresses these fundamental challenges beyond compute architecture, has successfully raised $43.0M from a syndicate of investors.
Matter Venture Partners, Viola Ventures, GHOVC, and Egis Technology participated in the round, backing TYLsemi's approach to critical components for the next generation of AI hardware.
TYLsemi Raises $43 Million To Launch First Full-Stack Chiplet Platform For Custom AI Silicon: TYLsemi, a San Jose-based chiplet platform company, has emerged from stealth and closed an oversubscribed $43 million early-stage funding round to accelerate development of AI infrastructure silicon.
The round was led by Matter Venture Partners with participation from Viola Ventures, GHOVC, Egis Technology and strategic investors across the global semiconductor and AI infrastructure ecosystem. The post TYLsemi Raises $43 Million To Launch First Full-Stack Chiplet Platform For Custom AI Silicon appeared first on Pulse 2.0.
Refr Sports
Refr Sports is assisting the referee industry by providing essential tools for referee assignors to excel. Addressing scheduling challenges and referee shortages, Refr Sports streamlines operations with user-friendly mobile and web applications. These applications enhance transparency, facilitate seamless payments, and simplify scheduling, transaction, networking, and communication processes. By aiding a struggling industry, Refr Sports aims to support over 105 million sports competitions annually in the U.S., offering a scalable and efficient solution for referee management. MN Twins Techstars '23
$2.0M Seed
today
Wugen
Allotera Therapeutics, Inc., headquartered in St. Louis, Missouri, is a clinical-stage biotechnology company focused on developing next-generation, allogeneic CAR-T cell therapies for cancer. Allotera’s proprietary gene-editing platform is designed to overcome key limitations of first-generation cell therapies, enabling scalable, off-the-shelf treatments with biologics-like cost of goods margins. The lead program, WU‑CART-007, targets CD7 and has demonstrated best-in-class efficacy in T-ALL/T-LBL, with the potential to be the first approved allogeneic CAR-T therapy for T-cell malignancies.
Largest funding rounds in AI on Signalbase right now.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Nuance Healthcare United States | Unknown | $19.7B | 1y ago |
| 2 |  Anthropic | Series f | $13.0B | 10mo ago |
Companies that recently closed a Unknown round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | %20(NZAX%3A%20CRP)%20(FSE%3A%20%203GRE).png&w=3840&q=75) Chatham Rock Phosphate (TSXV: NZP) (NZAX: CRP) (FSE: 3GRE) New Zealand | Unknown | $90.0K | today |
| 2 |  SCOTT New Zealand | Unknown | $12.0M | today |
$35.0M Series c
today
| 3 |  OpenAI United States | Unknown | $13.0B | 1y ago |
| 4 |  AIMAX United Kingdom | Unknown | $10.0B | 1y ago |
| 5 |  Preferred Networks, Inc. Japan | Unknown | ¥10.0B | 1y ago |
| 3 |  Revem | Unknown | $16.0K | today |
| 4 |  Caddie Chile | Unknown | $16.0K | today |
| 5 |  Battex Chile | Unknown | $16.0K | today |
Contacts, investors, buying intent signals & tech stack.
Trusted by 200+ sales teams
Matter Venture Partners
VENTURE
Viola Ventures
VC
Unlock 2 more investors and reach their contacts directly.
Start free trialUnlock 4 more key decision-makers at TYLsemi with verified emails and LinkedIn.
Start free trial.png&w=3840&q=75)
IDmize (by Zaldric)
Recently received
Iluvatar CoreX 天数智芯
Recently received
OnSite
Recently received
